Which Drugs Are Use For Destroy the Sex?

Use in Cancer

Goserelin acetate is approved to treat:

• Breast cancer is advanced. It is used as palliative treatment in premenopausal and perimenopausal women.
• Prostate cancer. It is used with flutamide and radiation therapy in localized prostate cancer. It is also used as palliative treatment in advanced prostate cancer.

Goserelin acetate is also being studied in conditions related to cancer.

Contraindications

• Goserelin is contraindicated in patients with hypersensitivity to goserelin, GnRH, or with Gonadotropin-Releasing Hormone (GnRH) Analogs hypersensitivity; anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported.
• cancer metastasis to bone
• diabetes
• high cholesterol
• low amount of magnesium in the blood
• low amount of calcium in the blood
• high amount of calcium in the blood
• low amount of potassium in the blood
• overweight
• high blood pressure
• a heart attack
• prolonged QT interval on EKG
• chronic heart failure
• abnormal EKG with QT changes from birth
• a stroke
• pregnancy
• obstruction of any part of the urinary tract
• tobacco smoking

Dosage

Prostate Cancer

For the palliative treatment of advanced carcinoma of the prostate:

• 3.6 mg or 10.8 mg subcutaneously into the upper abdominal wall once
• The 3.6 mg dosage may be repeated every 28 days.
• The 10.8 mg dosage may be repeated every 12 weeks.
• Intended for long-term administration unless clinically inappropriate.
• Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males: SubQ:
• Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant

OR

• 28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy)
• In combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should start 8 weeks prior to radiation therapy and continue during radiation.
• For the palliative treatment of advanced carcinoma of the prostate.

Endometriosis

• 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days. The recommended duration of therapy is 6 months.
• For the management of endometriosis, including pain relief and reduction of endometriotic lesions.

Breast Cancer–Palliative

• For use in the palliative treatment of advanced breast cancer: 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days
• Intended for long-term administration unless clinically inappropriate.
• For the palliative treatment of advanced breast cancer in pre-and perimenopausal women

Dose for Bleeding

• 1 or 2 of the 3.6 mg subcutaneous depot injections (with each depot given 4 weeks apart). When 1 depot is administered, surgery should be performed at 4 weeks.
• When 2 depots are administered, surgery should be performed within 2 to 4 weeks following the administration of the second depot.

Administration Technique

The proper method of administration of ZOLADEX is described in the instructions that follow.

• Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare an area of the anterior abdominal wall below the navel line with an alcohol swab.
  NOTE: Caution should be taken while injecting ZOLADEX into the anterior abdominal wall due to the proximity of the underlying inferior epigastric artery and its branches.
• Examine the foil pouch and syringe for damage. Remove the syringe from the opened foil pouch and hold the syringe at a slight angle to the light. Check that at least part of the ZOLADEX implant is visible.
• Grasp the red plastic safety tab and pull away from the syringe, and discard. Remove the needle cover. Unlike liquid injections, there is no need to remove air bubbles as attempts to do so may displace the ZOLADEX implant.
• Holding the syringe around the protective sleeve, using an aseptic technique, pinch the skin of the patient’s anterior abdominal wall below the navel line. With the bevel of the needle facing up, insert the needle at a 30 to 45-degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient’s skin.
  NOTE: The ZOLADEX syringe cannot be used for aspiration. If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and inject it with a new syringe elsewhere. Monitor patients for signs or symptoms of abdominal hemorrhage. Use extra care when administering ZOLADEX to patients with a low BMI and/or to patients receiving full-dose anticoagulation.
• Do not penetrate into muscle or peritoneum.
• To administer the ZOLADEX implant and to activate the protective sleeve, grasp the barrel at the finger grip and depress the plunger until you cannot depress it any further. If the plunger is not depressed fully, the protective sleeve will NOT activate. When the protective sleeve ‘clicks’, the protective sleeve will automatically begin to slide to cover the needle.
  NOTE: The needle does not retract.
• Withdraw the needle and allow the protective sleeve to slide and cover the needle. Dispose of the syringe in an approved sharps collector.

Side Effects

The Most Common

• headache
• hot flashes (a sudden wave of mild or intense body heat)
• sweating
• sudden reddening of the face, neck, or upper chest
• lack of energy
• loss of appetite
• breast pain or change in breast size in women
• decreased sexual desire or ability
• painful sexual intercourse
• vaginal discharge, dryness, or itching
• menstruation (periods)
• swelling of the hands, feet, ankles, or lower legs
• depression
• nervousness
• unable to control emotions and frequent mood changes
• difficulty falling asleep or staying asleep
• pain, itching, swelling, or redness at the place where the implant was inserted
• hives
• rash
• itching
• difficulty breathing or swallowing
• chest pain
• pain in the arms, back, neck, or jaw
• unusual weight gain
• slow or difficult speech
• dizziness or fainting
• weakness or numbness of an arm or leg
• bone pain
• not able to move legs
• painful or difficult urination
• frequent urination
• extreme thirst
• weakness
• blurred vision
• dry mouth
• nausea
• vomiting
• breath that smells fruity
• decreased consciousness

More Common

• Fast or irregular heartbeat
• Bone, muscle, or joint pain
• changes in the skin color of the face
• fainting
• fast or irregular breathing
• numbness or tingling of the hands or feet
• puffiness or swelling of the eyelids or around the eyes
• skin rash, hives, or itching
• sudden, severe decrease in blood pressure and collapse
• tightness in the chest
• troubled breathing
• pain, bruising, swelling, redness, oozing, or bleeding where the implant was injected;
• dizziness, trouble breathing, feeling light-headed (like you might pass out);
• high blood sugar – increased thirst, increased urination, dry mouth, fruity breath odor;
• high calcium levels – confusion, tiredness, nausea, vomiting, loss of appetite, constipation, increased thirst or urination, weight loss;
• heart attack symptoms – chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating; or
• signs of a blood clot – sudden numbness or weakness on one side of the body, chest pain, problems with vision or speech, pain or swelling in one leg.

RARE

• Anxiety
• deepening of voice
• increased hair growth
• mental depression
• mood changes
• Pain in the chest
• pain in the groin or legs (especially in the calves of the legs)
• Sudden sweating and feelings of warmth (also called hot flashes)
• Blurred vision
• burning, itching, redness, or swelling at the place of injection
• decreased interest in sexual intercourse
• dizziness
• headache
• nausea or vomiting
• swelling and increased tenderness of the breasts
• swelling of the feet or lower legs
• trouble sleeping
• weight gain
• Light, irregular vaginal bleeding
• stopping of menstrual periods
• Burning, dryness, or itching of the vagina
• pelvic pain
• Bone pain
• constipation
• decreased size of the testicles
• inability to have or keep an erection

Drug Interactions

Abacavir	Goserelin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.
Aceclofenac	Aceclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Acetaminophen	Goserelin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Aclidinium	Goserelin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Goserelin.
Acyclovir	Acyclovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
Adenosine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Adenosine.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Goserelin.
Albiglutide	The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin.
Albutrepenonacog	Goserelin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Aldesleukin	Goserelin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Goserelin.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Goserelin.
Allopurinol	Goserelin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate	Goserelin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Goserelin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
Alprazolam	Goserelin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Goserelin.
Amifampridine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amifampridine.
Amikacin	Goserelin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Amiodarone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amisulpride.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amitriptyline.
Ammonium	Goserelin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Goserelin.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Goserelin.
Amoxicillin	Goserelin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Goserelin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ampicillin	Goserelin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Goserelin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Anagrelide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Anagrelide.
Ancestim	Goserelin may decrease the excretion rate of Ancestim which could result in a higher serum level.
Antazoline	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Antazoline.
Antihemophilic	Goserelin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antipyrine	Antipyrine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Antithrombin III	Goserelin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine	Antrafenine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Apalutamide	Goserelin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Goserelin.
Apremilast	Goserelin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Goserelin.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin.
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Goserelin.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide.
Artemether	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Artemether.
Articaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Articaine.
Asenapine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Asenapine.
Astemizole	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Astemizole.
Atazanavir	The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Goserelin.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Goserelin.
Atropine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Atropine.
Auranofin	Goserelin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Goserelin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Azacitidine	Goserelin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Goserelin.
Azathioprine	Goserelin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Azelaic acid	Goserelin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Azithromycin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Azithromycin.
Aztreonam	Goserelin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacitracin	Bacitracin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Baclofen	Goserelin may decrease the excretion rate of Baclofen which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Goserelin which could result in a higher serum level.
Baricitinib	Goserelin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bedaquiline.
Bendroflumethiaz	Bendroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Goserelin which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Benserazide	Goserelin may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Goserelin.
Benznidazole	Goserelin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzyl alcohol.
Bepotastine	Goserelin may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Bepridil	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bepridil.
Berotralstat	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Berotralstat.
Bicisate	Goserelin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Goserelin.
Bismuth	Goserelin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Goserelin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Bisoxatin	Goserelin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bleomycin	Goserelin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Goserelin.
Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Goserelin.
Brivaracetam	Goserelin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Bromazepam	Goserelin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Bromocriptine	The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.

Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Goserelin.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Goserelin.
Budesonide	Goserelin may decrease the excretion rate of Budesonide which could result in a higher serum level.
Bumadizone	Bumadizone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Bupivacaine.
Bupropion	Goserelin may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Goserelin.
Buspirone	Goserelin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Butabarbital	Goserelin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Butriptyline.
Canagliflozin	The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	Goserelin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Capreomycin	Goserelin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capromab	Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Capsaicin.
Carbamazepine	Goserelin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Carbidopa	Goserelin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Carbinoxamine.
Carboplatin	Carboplatin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Carmustine	Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Carprofen	Carprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefaclor	Cefaclor may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefdinir	Goserelin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftaroline	Ceftaroline fosamil may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceftolozane	Goserelin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Celiprolol	The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Goserelin.
Cephalexin	Cephalexin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ceritinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib.
Certolizumab pegol	Goserelin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Goserelin.
Cevimeline	Goserelin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Chloral hydrate	Goserelin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Goserelin.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Chloroprocaine.
Chloroquine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chloroquine.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Goserelin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpheniramine.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpromazine.
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Goserelin.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Goserelin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Choline C 11	Goserelin may decrease effectiveness of Choline C 11 as a diagnostic agent.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Goserelin which could result in a higher serum level.
Choline salicylate	Goserelin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Goserelin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Goserelin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Goserelin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Goserelin may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium	Goserelin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Goserelin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Goserelin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Cidofovir	Cidofovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cilostazol	The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Goserelin.
Cimetidine	Goserelin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cinchocaine.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinnarizine.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinoxacin.
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin.
Cisapride	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cisapride.
Cisplatin	Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Citalopram	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram.
Clarithromycin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clarithromycin.
Clemastine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clemastine.
Clevidipine	Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	Goserelin may decrease the excretion rate of Clobazam which could result in a higher serum level.

clofarabine	Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Goserelin.
Clomipramine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clomipramine.
Clonazepam	Goserelin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clorazepic acid	Goserelin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clove oil	Goserelin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cocaine.
Colchicine	Goserelin may decrease the excretion rate of Colchicine which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Goserelin which could result in a higher serum level.
Colistin	Goserelin may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated	Goserelin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Corifollitropin	The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Goserelin.
Crizotinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Crizotinib.
Cyanocobalamin	Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Goserelin.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclosporine	Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Goserelin.
Dabigatran	Goserelin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dabrafenib	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin.
Dacarbazine	Goserelin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dalfampridine	Goserelin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dapagliflozin	The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.
Daptomycin	Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin.
Dasatinib	The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin.
Deferiprone	Goserelin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin.
Delafloxacin	The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Goserelin.
Delamanid	Goserelin may increase the QTc-prolonging activities of Delamanid.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Goserelin.
Desipramine	The risk or severity of QTc prolongation can be increased when Desipramine is combined with Goserelin.
Desloratadine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Desloratadine.
Desmopressin	Goserelin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
Desvenlafaxine	Goserelin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Deutetrabenazine.
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin.
Dexchlorpheniramine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine maleate.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Dexmedetomidine	Goserelin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexpanthenol	Goserelin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dextran	Goserelin may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Goserelin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Diazepam	Goserelin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl	Goserelin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine	Goserelin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Goserelin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Goserelin may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Goserelin which could result in a higher serum level.
Difluocortolone	Goserelin may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
Digitoxin	The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Goserelin.
Digoxin	Goserelin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Diltiazem	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Diltiazem.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dimenhydrinate.
Dimercaprol	Goserelin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl sulfoxide	Goserelin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Diphenhydramine.
Disopyramide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide.
Disulfiram	The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Goserelin.
DL-Methylephedrine	Goserelin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Goserelin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Dofetilide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dofetilide.
Dolasetron	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron.
Domperidone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone.
Dopamine	Goserelin may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Goserelin may decrease the excretion rate of Doripenem which could result in a higher serum level.
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Goserelin.
Doxacurium	Goserelin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Goserelin.
Doxycycline	Goserelin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Goserelin.
Dronedarone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Droperidol.
Drospirenone	Drospirenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa	Goserelin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.
Duloxetine	Goserelin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Dyclonine.
Dyphylline	Goserelin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Goserelin.
Edoxaban	Goserelin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Goserelin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efavirenz	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Efavirenz.
Eliglustat	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Eliglustat.
Emedastine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Emedastine.
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.
Enalaprilat	Goserelin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Goserelin.
Encorafenib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Goserelin.
Entrectinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib.
Enzalutamide	Goserelin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.

Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Goserelin.
Eplerenone	Eplerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Goserelin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Goserelin.
Erlotinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib.
Ertapenem	Goserelin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ertugliflozin	The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Goserelin.
Erythromycin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Goserelin.
Escitalopram	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Escitalopram.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Goserelin.
Estazolam	Goserelin may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estradiol	Goserelin may decrease the excretion rate of Estradiol which could result in a higher serum level.
Estradiol acetate	Goserelin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate	Goserelin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Goserelin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Goserelin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate	Goserelin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Goserelin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Goserelin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Ethambutol	Goserelin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Goserelin.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Etomidate	Goserelin may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel	Goserelin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Etoricoxib	Etoricoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Eucalyptus oil	Goserelin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Goserelin.
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin.
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Goserelin.
Felodipine	The risk or severity of QTc prolongation can be increased when Felodipine is combined with Goserelin.
Fenbufen	Fenbufen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Fenofibrate	Goserelin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fenofibric acid	Goserelin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Goserelin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Fentanyl	Goserelin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Goserelin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexinidazole	The risk or severity of adverse effects can be increased when Goserelin is combined with Fexinidazole.
Finerenone	Finerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate	Goserelin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flecainide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flecainide.
Floctafenine	Floctafenine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Florbetaben (18F)	Goserelin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Goserelin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	Goserelin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Goserelin.
Flucytosine	Goserelin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Fludeoxyglucose	Goserelin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil	Goserelin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fluocinolone	Goserelin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
Fluorouracil	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil.
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Goserelin.
Flupentixol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flupentixol.
Flurazepam	Goserelin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluspirilene.
Flutamide	Goserelin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Fluvoxamine	Goserelin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Folic acid	Goserelin may decrease the excretion rate of Folic acid which could result in a higher serum level.
Fomepizole	Goserelin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Goserelin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Goserelin may decrease the excretion rate of Formestane which could result in a higher serum level.
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Goserelin.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Goserelin.
Fosfomycin	Goserelin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Goserelin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Fostemsavir	The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Goserelin.
Framycetin	Framycetin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Gabapentin	Goserelin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gadobenic acid.
Gadodiamide	Goserelin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Gadofosveset	Goserelin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Goserelin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Goserelin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Goserelin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Goserelin.
Ganciclovir	Goserelin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Goserelin.
Gemcitabine	Goserelin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Gemfibrozil	Goserelin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gemifloxacin.
Gentamicin	Goserelin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib.
Gimeracil	Goserelin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Goserelin which could result in a higher serum level.
Glasdegib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib.
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.
Glycerol phenylbu	Goserelin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glymidine	The therapeutic efficacy of Glymidine can be decreased when used in combination with Goserelin.
Golodirsen	Goserelin may decrease the excretion rate of Golodirsen which could result in a higher serum level.

Granisetron	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Granisetron.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Grepafloxacin.
Guanethidine	Goserelin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Goserelin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Halofantrine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Halofantrine.
Haloperidol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Haloperidol.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Goserelin.
Hydralazine	Goserelin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Goserelin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Hydroxocobalamin	Goserelin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Goserelin.
Hydroxyethyl Starch	Goserelin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Goserelin.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin.
Ibuprofen	Ibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ibutilide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ibutilide.
Icatibant	Goserelin may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Goserelin which could result in a higher serum level.
Idarucizumab	Goserelin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Goserelin may decrease the excretion rate of Idebenone which could result in a higher serum level.
Ifosfamide	Goserelin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Iloperidone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Iloperidone.
Imatinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imatinib.
Imipramine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imipramine.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Goserelin.
Indapamide	Indapamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulfonic	Goserelin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indomethacin	Indomethacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Inosine pranobex	Goserelin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol	Goserelin may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Goserelin.
Insulin aspart	The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Goserelin.
Insulin beef	The therapeutic efficacy of Insulin beef can be decreased when used in combination with Goserelin.
Insulin degludec	The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Goserelin.
Insulin detemir	The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin.
Insulin glargine	The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin.
Insulin glulisine	The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Goserelin.
Insulin human	The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.
Insulin lispro	The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin.
Insulin pork	The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.
Iobenguane	Goserelin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Goserelin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Ioflupane I-123	Goserelin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Iopromide	Goserelin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Goserelin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Goserelin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Goserelin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	Goserelin may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab	Goserelin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Goserelin.
Isoniazid	Goserelin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Isosorbide	Isosorbide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Goserelin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosulfan blue	Goserelin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	Goserelin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Isoxicam	Isoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Goserelin.
Itraconazole	The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Goserelin.
Ivabradine	Ivabradine may increase the QTc-prolonging activities of Goserelin.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib.
Ixazomib	Goserelin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Kanamycin	Goserelin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Goserelin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketazolam	Goserelin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Goserelin.
Ketoprofen	Ketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Labetalol	Goserelin may decrease the excretion rate of Labetalol which could result in a higher serum level.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Goserelin.
Lamivudine	Goserelin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Goserelin.
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Goserelin.
Latamoxef	Latamoxef may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ledipasvir	Goserelin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Goserelin.
Lenalidomide	Goserelin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Lenvatinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lenvatinib.
Lesinurad	Goserelin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levacetylmethadol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Goserelin.
Levocarnitine	Goserelin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Goserelin.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin.
Levomenthol	The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Goserelin.
Levomilnacipran	Goserelin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Goserelin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levosimendan	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levosimendan.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Goserelin.
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
Liothyronine	Goserelin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.
Lisinopril	Goserelin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Lithium carbonate	Goserelin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Goserelin which could result in a higher serum level.

Lixisenatide	The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Goserelin.
Lofexidine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lofexidine.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lomefloxacin.
Loperamide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Loperamide.
Lopinavir	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Goserelin.
Loracarbef	Loracarbef may decrease the excretion rate of Goserelin which could result in a higher serum level.
Lorazepam	Goserelin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Lorcaserin	Goserelin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
Lorpiprazole	Goserelin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Losartan	The risk or severity of QTc prolongation can be increased when Losartan is combined with Goserelin.
Loxoprofen	Loxoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Lubiprostone	Goserelin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lumefantrine.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Goserelin.
Macimorelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Macimorelin.
Macitentan	Goserelin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium car	Goserelin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chl	Goserelin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydr	Goserelin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium trisi	Goserelin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Goserelin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Goserelin.
Mecamylamine	Goserelin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Mecasermin	The therapeutic efficacy of Mecasermin can be decreased when used in combination with Goserelin.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Medroxyprogester	Goserelin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Goserelin.
Megestrol acetate	Goserelin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Meloxicam.
Memantine	Goserelin may decrease the excretion rate of Memantine which could result in a higher serum level.
Meperidine	Goserelin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Mepivacaine.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Goserelin.
Meropenem	Goserelin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mesoridazine.
Metamfetamine	Goserelin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Goserelin which could result in a higher serum level.
Metaxalone	Goserelin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.
Methadone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Methadone.
Methazolamide	Methazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	Goserelin may decrease the excretion rate of Methimazole which could result in a higher serum level.
Methotrexate	Methotrexate may decrease the excretion rate of Goserelin which could result in a higher serum level.
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Goserelin.
Methoxsalen	Goserelin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Goserelin.
Methyldopa	Goserelin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methylene blue	Goserelin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Methylnaltrexone	Goserelin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methyltestosterone	Goserelin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin.
Metolazone	Metolazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Goserelin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Goserelin.
Metyrapone	Goserelin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Midazolam	Goserelin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Mifepristone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mifepristone.
Migalastat	Goserelin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.
Milnacipran	Goserelin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Goserelin may decrease the excretion rate of Milrinone which could result in a higher serum level.
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Goserelin.
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Goserelin.
Mizolastine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mizolastine.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mobocertinib.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Goserelin.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Goserelin.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin.
Moxisylyte	Goserelin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Muzolimine	Muzolimine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate	Goserelin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
Mycophenolic acid	Goserelin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
N-acetyltyrosine	Goserelin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Nadolol	Goserelin may decrease the excretion rate of Nadolol which could result in a higher serum level.
Naldemedine	Goserelin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nalidixic acid.
Nalmefene	Goserelin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Goserelin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Goserelin which could result in a higher serum level.
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.
Nedaplatin	Goserelin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Goserelin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	Goserelin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Nelfinavir	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Goserelin.
Neomycin	Goserelin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Goserelin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Goserelin.
Nicorandil	Goserelin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nifedipine.
Nilotinib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilotinib.
Nilutamide	Goserelin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nilvadipine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilvadipine.

Nimesulide	Nimesulide may decrease the excretion rate of Goserelin which could result in a higher serum level.
Nimodipine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nimodipine.
Nisoldipine	Goserelin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Goserelin.
Nitric Oxide	Goserelin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitrofurantoin	Goserelin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitroprusside	Goserelin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Goserelin.
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Goserelin.
Octinoxate	Goserelin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ofloxacin.
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Goserelin.
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Goserelin.
Olsalazine	Olsalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ondansetron	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ondansetron.
Opium	Goserelin may decrease the excretion rate of Opium which could result in a higher serum level.
Orphenadrine	The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Goserelin.
Oseltamivir	Goserelin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Oxacillin	Goserelin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Oxatomide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxatomide.
Oxazepam	Goserelin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxetacaine.
Oxybenzone	Goserelin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Oxyquinoline	Goserelin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.
Pacritinib	The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Goserelin.
Paliperidone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Paliperidone.
Palonosetron	Goserelin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Panobinostat	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Panobinostat.
Pantoprazole	Goserelin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Papaverine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine.
Parecoxib	Parecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Paromomycin	Paromomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Goserelin.
Patent Blue	Goserelin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pazopanib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Goserelin.
Pegaptanib	Goserelin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Goserelin.
Pemetrexed	Goserelin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Penbutolol	Goserelin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Pentaerythritol	Goserelin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	The therapeutic efficacy of Pentamidine can be decreased when used in combination with Goserelin.
Pentastarch	Goserelin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Goserelin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Goserelin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Pentostatin	Goserelin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentoxifylline	Goserelin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Perflutren	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Perflutren.
Perhexiline	The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Goserelin.
Perindopril	Goserelin may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Goserelin may decrease the excretion rate of Permethrin which could result in a higher serum level.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Phenelzine	Goserelin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin.
Phenol	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Phenol.
Phentolamine	Goserelin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
Pholcodine	Goserelin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Goserelin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Goserelin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Picosulfuric acid	Goserelin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimozide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pimozide.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Goserelin.
Pindolol	Goserelin may decrease the excretion rate of Pindolol which could result in a higher serum level.
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.
Piperacillin	Goserelin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Piracetam	Goserelin may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Piroxicam	Piroxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
Pitolisant	Goserelin may increase the QTc-prolonging activities of Pitolisant.
Plazomicin	Goserelin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Goserelin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Goserelin.
Posaconazole	The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Goserelin.
Potassium	Potassium may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Goserelin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium	Goserelin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Goserelin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Goserelin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium	Goserelin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Goserelin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate	Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralidoxime	Goserelin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pramipexole	Goserelin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Pramocaine.
Prasugrel	Goserelin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Prednisone	Goserelin may decrease the excretion rate of Prednisone which could result in a higher serum level.

Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Goserelin.
Prenylamine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prenylamine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Prilocaine.
Primaquine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Primaquine.
Probenecid	Goserelin may decrease the excretion rate of Probenecid which could result in a higher serum level.
Probucol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Probucol.
Procainamide	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Procainamide.
Procaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Procaine.
Procaine benz	Goserelin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prochlorperazine.
Promazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Promazine.
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Goserelin.
Propafenone	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone.
Propantheline	Goserelin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Proparacaine.
Propiverine	Goserelin may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Goserelin.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Propoxycaine.
Propranolol	Goserelin may decrease the excretion rate of Propranolol which could result in a higher serum level.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Goserelin.
Prucalopride	Goserelin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Goserelin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Goserelin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyridoxine	Goserelin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Pyrithione	Goserelin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quetiapine.
Quinethazone	Quinethazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinidine.
Quinine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine.
Rabeprazole	Goserelin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Ramelteon	Goserelin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ranitidine	Goserelin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Ranolazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ranolazine.
Rasagiline	Goserelin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Relugolix	The risk or severity of QTc prolongation can be increased when Relugolix is combined with Goserelin.
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.
Reserpine	Goserelin may decrease the excretion rate of Reserpine which could result in a higher serum level.
Resorcinol	Goserelin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin	Goserelin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribociclib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ribociclib.
Ribostamycin	Goserelin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilpivirine	The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Goserelin.
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Goserelin.
Ritonavir	The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Goserelin.
Rivaroxaban	Goserelin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	Goserelin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Roflumilast	Goserelin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Romidepsin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ropivacaine.
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Goserelin.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Roxithromycin.
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Goserelin.
Ruxolitinib	Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sacubitril	Goserelin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Goserelin.
Salicylamide	Salicylamide may decrease the excretion rate of Goserelin which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Salmeterol	The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin.
Salmon calcitonin	Goserelin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Goserelin which could result in a higher serum level.
Saquinavir	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Saquinavir.
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.
Secobarbital	Goserelin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Selenious acid	Goserelin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Goserelin may decrease the excretion rate of Selenium which could result in a higher serum level.
Semaglutide	The therapeutic efficacy of Semaglutide can be decreased when used in combination with Goserelin.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Goserelin.
Sibutramine	Goserelin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.
Sodium acetate	Goserelin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium auro	Goserelin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium fluoride	Goserelin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Goserelin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Goserelin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Goserelin.
Solriamfetol	Goserelin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Goserelin.
Sorbitol	Goserelin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin.
Sotalol	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sparfloxacin.
Spironolactone	Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol	Goserelin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Streptomycin	Goserelin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Strontium chloride	Goserelin may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Goserelin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Sulbactam	Goserelin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Goserelin.
Sulfamethoxazole	The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Goserelin.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
Sulfisoxazole	The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Goserelin.
Sulindac	Sulindac may decrease the excretion rate of Goserelin which could result in a higher serum level.
Sulpiride	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sulpiride.
Sultopride	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sultopride.
Sumatriptan	Goserelin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The therapeutic efficacy of Sunitinib can be decreased when used in combination with Goserelin.

Tacrolimus	The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Goserelin.
Tadalafil	Goserelin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Goserelin.
Tamsulosin	Goserelin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Tasimelteon	Goserelin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Technetium T	Goserelin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium	Goserelin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium	Goserelin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium Tc	Goserelin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Teduglutide	Goserelin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Goserelin may decrease the excretion rate of Tegafur which could result in a higher serum level.
Telavancin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telavancin.
Telithromycin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telithromycin.
Temazepam	Goserelin may decrease the excretion rate of Temazepam which could result in a higher serum level.
Temozolomide	Goserelin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Tenofovir	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Goserelin.
Tenofovir	Tenofovir disoproxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Goserelin.
Terfenadine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terfenadine.
Terlipressin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terlipressin.
Testolactone	Goserelin may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	Goserelin may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone	Goserelin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone	Goserelin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone pro	Goserelin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Testosterone undec	Goserelin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Tetracaine.
Tetracycline	Goserelin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetradecyl	Goserelin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thiabendazole	Goserelin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Thiethylperazine	Goserelin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Thioridazine	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Thioridazine.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Goserelin.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Ticlopidine	Goserelin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
Tiludronic acid	Goserelin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	The risk or severity of QTc prolongation can be increased when Timolol is combined with Goserelin.
Tinidazole	Goserelin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tiopronin	Goserelin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Goserelin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tirofiban	Goserelin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tirzepatide	The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Goserelin.
Tixocortol	Goserelin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Goserelin.
Tobramycin	Goserelin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocopherol	Goserelin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.
Tolcapone	Goserelin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Goserelin which could result in a higher serum level.
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Goserelin.
Tolvaptan	Tolvaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Goserelin may decrease the excretion rate of Topiramate which could result in a higher serum level.
Topotecan	Goserelin may decrease the excretion rate of Topotecan which could result in a higher serum level.
Torasemide	Torasemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Toremifene	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Toremifene.
Tositumomab	Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Tramadol	Goserelin may decrease the excretion rate of Tramadol which could result in a higher serum level.
Trametinib	Goserelin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Goserelin.
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Goserelin.
Triamterene	Triamterene may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Goserelin may decrease the excretion rate of Triazolam which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
Triclabendazole	The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Goserelin.
Triethylenetetram	Goserelin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	Goserelin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Goserelin.
Trimethadione	The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Goserelin.
Trimethoprim	Goserelin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Trimetrexate	Goserelin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Goserelin.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Goserelin.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin.
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.
Tropisetron	Goserelin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Trovafloxacin.
Vaborbactam	Goserelin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
Valbenazine	Goserelin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
Valganciclovir	Goserelin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valproic acid	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid.
Vancomycin	Goserelin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vandetanib.
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Goserelin.
Varenicline	Goserelin may decrease the excretion rate of Varenicline which could result in a higher serum level.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vemurafenib.
Venlafaxine	Goserelin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Verapamil	Goserelin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Goserelin.
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Goserelin.
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.
Viloxazine	Goserelin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Goserelin.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Goserelin.
Vortioxetine	Goserelin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category:

Pregnancy

This drug is contraindicated during pregnancy unless it is being used for the palliative treatment of advanced breast cancer. This drug can harm a developing fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. There is an increased risk of pregnancy loss due to hormone changes caused by this drug. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.

Lactation

A decision should be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother; some experts consider use to be contraindicated.

How should this medicine be used?

Goserelin comes as an implant to be inserted with a syringe subcutaneously (under the skin) in your stomach area by a doctor or nurse in a medical office or clinic. An implant with 3.6 mg of goserelin is usually inserted every 4 weeks. An implant with 10.8 mg of goserelin is usually inserted every 12 weeks. The length of your treatment depends on the condition being treated and your response to the medication. Your doctor will determine how long you should use the goserelin implant.

Goserelin may cause an increase in certain hormones in the first few weeks after insertion of the implant. Your doctor will monitor you carefully for any new or worsening symptoms during this time.

What special precautions should I follow?

Before receiving a goserelin implant,

• tell your doctor and pharmacist if you are allergic to goserelin, histrelin (Supprelin LA, Vantas), leuprolide (Eligard, Lupron), nafarelin (Synarel), triptorelin (Trelstar), any other medications, or any of the ingredients in goserelin implant. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: medications for seizures or oral steroids such as dexamethasone (Decadron, Dexpak), methylprednisolone (Medrol), and prednisone (Sterapred). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
• tell your doctor if you have a history of drinking alcohol or using tobacco products for a long period of time, or if you or anyone in your family has or has ever had osteoporosis (a condition in which the bones become thin and weak and break easily), or if you have or have ever had a compressed spinal cord, diabetes, unusual vaginal bleeding, urinary obstruction in men (blockage that causes difficulty urinating), or heart or liver disease.
• tell your doctor if you are pregnant or plan to become pregnant. Goserelin implants should not be used in pregnant women, except for the treatment of advanced breast cancer. Call your doctor right away if you think you have become pregnant during your treatment. Goserelin implant may harm the fetus. You should not plan to become pregnant while using a goserelin implant or for 12 weeks after your treatment. Your doctor may perform a pregnancy test or tell you to begin your treatment during your menstrual period to be sure that you are not pregnant when you begin using the goserelin implant. You will need to use a reliable nonhormonal method of birth control to prevent pregnancy while you are using a goserelin implant and for 12 weeks after your treatment. Talk to your doctor about the types of birth control that are right for you, and continue to use birth control even though you should not have regular menstrual periods during your treatment. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with a goserelin implant.

References

Show More